Informations générales (source: ClinicalTrials.gov)

NCT00802243 Statut inconnu
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid. An Open Prospective Study (ARABUL)
Interventional
  • Pemphigoïde bulleuse
Phase 2
University Hospital, Limoges (Voir sur ClinicalTrials)
septembre 2007
29 juin 2024
Bullous pemphigoid (BP) is the most common blistering auto-immune disease of skin with an incidence estimated to 400 new cases per year. Topical corticosteroid therapy is considered the standard treatment for bullous pemphigoïd in 2002. Topical corticosteroid requires an initial large hospitalization during the acute phase and rehospitalization during relapse. The usefulness of immunosuppressive drugs have suggested by uncontrolled study. In this way, leflunomide could be an alternative therapy, and to reduce relapse and/or resistance risks. This study could prove the efficacity of leflunomide, associated with short time topical corticosteroids.
 Voir le détail

Etablissements

Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Bordeaux University Hospital - 33604 - Pessac - France Marie Sylvie DOUTRE, MD Recrutement non commencé Contact (sur clinicalTrials)
Limoges University Hospital - 87042 - Limoges - France Christophe BEDANE, MD En recrutement Contact (sur clinicalTrials)
Toulouse University Hospital - 31059 - Toulouse - France Carle PAUL, MD Recrutement non commencé Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- Adult ≥ 65 years old

- Bullous pemphigoid :

- Newly diagnosed bullous pemphigoid : No treatment or topical corticosteroids
therapy for less than one month

- BP diagnosed : Resistance of the BP to the treatment or recurrence 6 months at
least after diagnosis

- Follow up monthly during one year accepted

- Written Inform Consent


- None